
Mini-Review

Pluripotent Stem Cell-Derived Human Tissue: Platforms to Evaluate Drug Metabolism and Safety

Jose Meseguer-Ripolles,¹ Salman R. Khetani,² Javier G. Blanco,³ Mairi Iredale,¹ and David C. Hay^{1,4} 

Received 22 September 2017; accepted 16 November 2017

Abstract. Despite the improvements in drug screening, high levels of drug attrition persist. Although high-throughput screening platforms permit the testing of compound libraries, poor compound efficacy or unexpected organ toxicity are major causes of attrition. Part of the reason for drug failure resides in the models employed, most of which are not representative of normal organ biology. This same problem affects all the major organs during drug development. Hepatotoxicity and cardiotoxicity are two interesting examples of organ disease and can present in the late stages of drug development, resulting in major cost and increased risk to the patient. Currently, cell-based systems used within industry rely on immortalized or primary cell lines from donated tissue. These models possess significant advantages and disadvantages, but in general display limited relevance to the organ of interest. Recently, stem cell technology has shown promise in drug development and has been proposed as an alternative to current industrial systems. These offerings will provide the field with exciting new models to study human organ biology at scale and in detail. We believe that the recent advances in production of stem cell-derived hepatocytes and cardiomyocytes combined with cutting-edge engineering technologies make them an attractive alternative to current screening models for drug discovery. This will lead to fast failing of poor drugs earlier in the process, delivering safer and more efficacious medicines for the patient.

KEY WORDS: drug development; heart; liver; pluripotent stem cell; toxicity.

INTRODUCTION

Despite improvements in drug screening, there is still a high percentage of drug attrition during development. This presents in either in pre-clinical modeling, clinical trials or after drug approval, with greater expense incurred the further along the pipeline the compounds are removed. Therefore, fast failing is key to improving the success and the cost of human drug development. The percentage of drug failure at phase II and phase III is high and the main reasons for failure are the lack of efficacy, 48% in phase II and 55% in phase III, and safety, 25% in phase II and 14% in phase

III (1). A recent study analyzed the main reasons for a drug withdrawn from the market because of adverse effects from 1950 to 2014. Hepatotoxicity (18%) represented the first reason for drug withdrawal followed by immune-related reactions (17%) and with cardiotoxicity third (14%). Hepatotoxicity and cardiotoxicity represent serious concerns in drug development. Side toxic effects are often detected at later stages of the development or even after the drug approval. Because of that, there is a need to improve current screening models to improve the early detection of hepatotoxic and cardiotoxic drugs (2). Although high-throughput screening platforms permit the testing of large compound libraries during drug development, the high attrition rates demonstrate the need for improved screening platforms and more reliable pre-clinical models. An essential component of this is to improve model fidelity (for a detailed review see (3)). Key to this is our ability to recapitulate organ physiology 'in the dish'. Improvements in this space will likely lead to improved safety, efficacy and reduced development costs (3).

Current cell-based models used within industry rely heavily on immortalized cell lines, usually derived from human tumors. These models have advantages, such as cost-effective scale up and well to well consistency. Additionally, these cell lines are amenable to genetic engineering, permitting gain and loss of function analysis. While these models demonstrate advantages, they offer limited biological relevance when compared to the

The original version of this article was revised: The original version of the published article contained errors throughout the text, which were introduced by the typesetter when performing the author's proof corrections.

¹ MRC Centre for Regenerative Medicine, 5 Little France Drive, Edinburgh, EH16 4UU, UK.

² University of Illinois at Chicago, Bioengineering (MC 063) 851 S Morgan St, 218 SEO, Chicago, Illinois 60607, USA.

³ School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA.

⁴ To whom correspondence should be addressed. (e-mail: davehay@talktalk.net)

intact organ and primary cell types. Currently, primary cells and tissue slices are the gold standard for drug discovery, as they exhibit greater resemblance to the organ of interest. There are however drawbacks with these resources. The main disadvantages of using primary cell types or tissue slices are their labor intensive isolation from diseased organs, the scarcity of donor tissue, the rapid loss of cell phenotype, and significant batch to batch variation (4).

Stem cell technology has shown promise in drug screening (5,6) and has been proposed as a suitable alternative to overcome the above-mentioned limitations with primary cell types. Current advances in embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) differentiation protocols better mimic primary cells than the immortalized lines (7). This, in combination with enabling techniques such as 3D culture, microfabrication, fluid flow, and cell encapsulation, offers the prospect of more accurate models to study organ biology. Through model refinement and cost-effective scale up, it is now possible to prototype systems for drug development scientists from defined genetic backgrounds to study and better understand the biology behind idiosyncratic drug-induced liver injury (8–10). The power of these systems in combination with label free technologies and multiparametric data analysis offer exciting prospects for the future (3,6,11,12). In this concise review, we will highlight some past and present efforts in the field.

HUMAN DRUG METABOLISM

The liver plays a central role in drug disposition; it is responsible for drug uptake, metabolism and excretion. Several factors are involved in the off-target effects of drugs with differential metabolism playing a key role. Cytochrome P450 enzymes play an important role during drug metabolism, with five family members (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) responsible for the metabolism of approximately 90% of marketed drugs. Genetic polymorphisms in the CYP450 family members affects drug metabolism, efficacy and safety (13,14). Polymorphisms in phase II enzymes, such as UDP-glucuronosyltransferases, N-acetyltransferases, and glutathione S-transferases, and ABC transporters are also known to influence metabolism and drug exposure (for a review please see (14)). Following drug metabolism, the metabolites are an important concern. Those can be active and provide patient benefit; however, they also expose the organ to adverse events, including endoplasmic reticulum stress (19,20). This can lead to alterations in cell signaling pathways that can alter the cell fate upon toxic insult such as NF- κ B and Nrf-2 (15,16). Mitochondrial stress is also evident, altering cellular ATP and reactive oxygen species levels triggering cell death pathways (17,18). Drug metabolism and cell stress are therefore key concerns during the drug development process to reduce possible side effects of new drugs.

Detection of potential cardiotoxic drugs is also important due to the percentage of heart disease that exists in the population (21). Drug metabolites can cause cardiotoxicity via changes in action potentials and altered ion channel activity. The most common drug-induced cardiotoxicity is the Torsade de Pointes (TdP), a type of ventricular arrhythmia caused by ion channel blocking. Additionally, the Ether- α -go-go-Related Gene (hERG) channel is commonly blocked by drug interaction which can result in the development of long QT syndrome (22). Notably, multiple drugs

can alter QT interval prolongation increasing the risk of cardiac failure, including anticancer drug metabolites (23,24).

The factors discussed above are important considerations for drug development. One major consideration is the diversity of the population, which is not captured by many *in vitro* models. This requires the development of more sophisticated systems for human drug development. We believe that stem cell-based technologies have the power to capture variability observed in the population. Stem cell-derived hepatocytes and cardiomyocytes have been used successfully to study drug metabolism on defined genetic backgrounds, providing critical proof of concept that pluripotent stem cell-derived cell types are enabling for human drug development (for reviews see 25 and 26).

HEPATOCYTE SCREENING MODELS

The gold standard model for the study of drug metabolism during drug development is the primary hepatocyte. The main disadvantages of primary hepatocytes are their rapid loss of phenotype post isolation and isolation costs (4, 23). Therefore, researchers have searched for more accessible and cheaper alternatives. Cancer-derived cell lines, such as HepG2, HuH-7, Hep3B, or Fa2N-4, and HepaRG have been used to characterize some determinants of drug metabolism (24,27,28). Pluripotent cell-derived models have been proposed as an alternative cell source for screening (6,29,30). In many cases, pluripotent cell-derived models exhibit drug sensitivities patterns similar to primary cells (5,7,31–33). Moreover, the use of pluripotent stem cells allows the user to derive somatic cells from defined background, thereby offering insight into idiosyncratic DILI (34,35). To date, most of the work has focused on monolayer hepatocyte systems derived from induced pluripotent stem cells, through defined and reproducible differentiation protocols. Despite these advances, monolayer cultures of hepatocytes face significant limitations and do not emulate the complexity of the liver in terms of tissue organization, blood flow, and different cell-cell interactions. To overcome these limitations, organoid or spheroid models have been developed showing promising results (36,37). Although they require more complex differentiation protocols, organoids/spheroids better recapitulate human tissue structure and display more mature and functional phenotype such as improved cytochrome P450 3A4 activity, greater expression of Phase II and III enzymes, combined with reduced fetal gene expression and longer lifespan (38). While promising the current challenges that face the “3D field” is cost-effective manufacture, experimental reproducibility and automated scale-up for application.

Hepatocyte Differentiation from Pluripotent Stem Cells

Several groups have established differentiation protocols that allow the efficient differentiation of human pluripotent stem cells into hepatocyte-like cells (HLCs). Hepatocyte differentiation attempts to recreate aspects of human liver development using growth factors and small molecules (5,12,39–50)(summarized in Table I).

Hepatocyte monolayer differentiation systems usually consist of stage-wise approach where the stem cell populations are driven to definitive endoderm using growth factors such as, activin A and Wnt3a (41,51) (Fig. 1). This is followed by hepatic

Pluripotent Stem Cell-Derived Human Tissue

progenitor cell specification (42,43,49) and hepatocyte maturation (39,44–48,50,52) (Fig. 1). These protocols produce HLCs that express hepatocyte markers such as HNF4a, albumin, and cytochrome P450 proteins (Fig. 1) (6,8,29,30). Advantages of the 2D systems include the automated and cost effective scale up, and limited batch variation, making them ideal prototypes for drug screening. However, 2D systems do face some limitations, such as the mixture of fetal and adult hepatocyte traits, limited tissue structure and as a consequence cannot recapitulate all situations that occur *in vivo* (53).

HLCs as a Tool for Disease Modeling and Drug Screening

Recent advances in the last decade have demonstrated the potential of HLCs as a tool to model human diseases and drug exposure and some examples follow. Rashid *et al.* (46) and Cayo *et al.* (54) produced HLCs from patient-derived human iPSC cell lines which accurately modeled human metabolic liver disease. Similarly, Graffman *et al.* developed a system to study non-alcoholic fatty liver disease from human pluripotent stem cells, inducing fat storage in HLCs and detecting dysregulated expression of metabolism-associated genes (55). More recently, a study performed by Kim *et al.* (56) provided proof of concept that HLCs can predict drug-induced hepatotoxicity in which the immune system played a role. HLCs secreted pro-inflammatory cytokines and chemokines, such as TNF- α , interleukin1 β , interferon α , and chemokine (C-C motif) ligand 5, which activated immune cell lines. Additionally, Lucendo-Villarin *et al.* (57) showed how HLCs can be used to study fetal hepatotoxicity when exposed to tobacco derivatives. Relative to other types of hepatocyte sources, HLCs were found to be more sensitive than the cancer cell line HepG2 (58) and exhibit a comparable response to primary hepatocytes when challenged with toxins (33,58), suggesting that HLCs are suitable for drug screening. Drug repurposing is another potential use of stem cell-based technologies. While continued research into the cell niche is required to further improve the HLC phenotype, the studies described above evidence the power of stem cell-derived HLCs to model human disease and improve drug discovery.

In addition to the above, collections of iPSC-derived cell lines from multiple donors would facilitate studies aimed to determine whether “donor specific” factors modify the pharmacological profile of drug candidates. For example, panels of human iPSC-derived HLCs with distinct CYP450 genotypes would be useful to uncover potentially significant sources of interindividual variability in drug metabolism. However, widespread implementation of this attractive paradigm is limited by difficulties inherent to the production and characterization of relatively large numbers of iPSC-derived cell lines (59). Furthermore, it remains to be determined whether the impact of “donor specific” factors such as functional genetic polymorphisms and epigenetic signatures is closely reproduced within the milieu of iPSC-derived cell types. In this regard, a recent study by Takayama *et al.* showed that HLCs exhibit interindividual differences in drug metabolism that are similar to the ones found in the originating primary human hepatocytes (PHHs) (31). The authors generated 12 individual HLCs cell lines and performed extensive comparisons with the originating PHHs by using an array of phenotypic assays. Notable findings included CYP1A2, CYP2C9, and CYP3A4 activities between HLCs vs PHHs exhibited good correlation ($r^2 > 0.7$); HLCs and PHHs

displayed similar CYP2C9-mediated metabolism for the hepatotoxic substrate benzbromarone; and the impact of CYP2D6 polymorphic variants on CYP2D6 activity was comparable between HLCs and the originating PHHs. The authors noted that future studies should examine whether HLCs differentiated from other cell can also recapitulate interindividual differences in drug metabolism.

Engineering Approaches to Improve HLC Differentiation and Maturation

Randomly distributed 2D cultures/co-cultures containing primary human hepatocytes (PHHs) and HLCs are straightforward to create but do not allow control over homotypic/heterotypic cell-cell interactions and cell-ECM signaling that are known to affect liver functions *in vivo*. In contrast, several engineering tools, such as cellular microarrays, protein micropatterning, microfluidics, biomaterial scaffolds, and bioprinting, now allow precise control over the cellular microenvironment to enhance hepatocellular function. Long-term (4+ weeks) stabilization of function typically requires cocultivation with liver- or non-liver-derived non-parenchymal cell types (52). For instance, Berger *et al.* developed a micropatterned co-culture platform (iMPCC) in which human iPSC-derived HLCs were organized into collagen-coated domains of empirically optimized dimensions and subsequently surrounded by 3 T3-J2 murine embryonic fibroblasts (60), a cell type that expresses molecules present in the liver (61–62). In contrast to phenotypically declining HLC monolayers, iMPCCs displayed high and stable liver functions (i.e., CYP450 enzyme activities) and a significant reduction in fetal markers (i.e., alpha-fetoprotein) for 4+ weeks. Ware *et al.* subsequently treated iMPCCs in 96-well plates with 47 drugs for 6 days, and evaluated function/viability endpoints (albumin, urea, and ATP) over time (32). Results showed 65% sensitivity (24 of 37 hepatotoxic drugs) and 100% specificity (9 of 9 non-liver-toxic drugs) in iMPCCs, which were remarkably similar to the sensitivity/specificity (70%/100%) in MPCCs containing PHHs treated with the same drugs for 5–9 days (63). Such studies suggest iMPCC utility for an initial hepatotoxicity screen in early drug development.

In addition to the MPCC platform, PHHs (64), stem cell-derived HLCs (65,66), and adult human liver bipotential cells (67) can be differentiated and stabilized in 3D spheroids/organoids, which leads to the establishment of homotypic cell-cell interactions and the presence of ECM proteins within and around the cells. Hepatic spheroids can spontaneously form on non-treated culture plates or those coated with various polymers (64,68). Such spheroids/organoids have been shown to display high viability/functions and *in vivo*-like responses to drugs (64); however, it is difficult to control the spheroid size and smaller spheroids can merge to form larger spheroids with necrotic cores due to poor diffusion of oxygen/nutrient. To mitigate such a challenge, specialized plates and scaffolds have been developed to direct the assembly of uniformly sized spheroids that remain separated for interrogation following drug/stimuli treatment. For instance, Takayama *et al.* utilized a nanopillar plate to create HLC spheroids, which were more sensitive to drug toxicity than HepG2 spheroids (65); however, HLCs spheroids displayed lower sensitivity than conventional PHH monolayers,

Table 1. A summary of the differentiation methodologies developed for hepatocyte like cell production from pluripotent stem cells

Substrate	Definitive endoderm induction	Days	Hepatic specification	Days	Hepatic maturation	Days	% Albumin + HNFa expression	CYP450 activity	References
MEFs	AA	3	FGF4, BMP2	5	OSM, HGF, BSA, FGF4, HGF, OSM, Dex	5	70 (ALB)	CYP 2B1/2	Cai <i>et al.</i> 2007 (39)
MEFs/Collagen I	AA, FBS, KOSR	5	FGF4, HGF, KOSR	3	+ FGF4, HGF, OSM, Dex	2	67.4	NT	Agarwal <i>et al.</i> 2008 (40)
Matrigel	AA, Wnt3A	3	1% DMSO, 20% KOSR	5	FGF4, HGF, OSM, Dex	9	90	CYP 1A2 CYP 3A4	Hay <i>et al.</i> 2008 (41)
MEFs	AA, FGF2	3	1% DMSO, HGF	8	Dex	3	55.5	CYP 1A2 CYP 3A	Basma <i>et al.</i> 2009 (42)
MEFs	AA	5	FGF4, BMP2	5	HGF + OSM	5	80	NT	Si-Tayeb <i>et al.</i> 2010 (43)
Matrigel	AA, Wnt3A	3	1% DMSO, 20% KOSR	5	HGF, OSM, HC	5	70-90	CYP 1A2 CYP 3A4	Sullivan <i>et al.</i> 2010 (44)
Matrigel	AA, BMP4, FGF2	2	FGF10	3	FGF4, HGF, EGF	8	NQ	CYP 3A	Touboul <i>et al.</i> 2010 (45)
Fibronectin	AA, FGF2, CHIR99021	1	AA	5	HGF, OSM	17	83	CYP 3A4	Rashid <i>et al.</i> 2010 (46)
MEFs	AA, FGF2	1							
Matrigel	AA, Wnt3a, HGF	3	1% DMSO, 20% KOSR	5	HGF, OSM	7	NQ	CYP 3A4	Chen <i>et al.</i> 2012 (47)
Matrigel	AA, Wnt3a	3	1% DMSO, 20% KOSR	5	HGF, OSM, HC	9	90	CYP 1A2 CYP 3A4	Szkolnicka <i>et al.</i> 2014 Rashidi <i>et al.</i> 2016 (5,48)
Matrigel	AA	3	FGF4, BMP2	4	OSM, Dex	8	NQ	CYP 2B6	Song <i>et al.</i> 2009 (49)
Laminin	AA, Wnt3a	3	HGF, KGF	6	HGF, OSM, HC	9	90	CYP 1A2 CYP 3A4	Cameron <i>et al.</i> 2015 Wang <i>et al.</i> 2017 (12,50)

MEFs mouse embryonic fibroblasts, AA activin A, Dex dexamethasone, OSM oncostatin M, FGF2 fibroblast growth factor 2, FGF4 fibroblast growth factor 4, FGF10 fibroblast growth factor 10, BSA bovine serum albumin, EGF epidermal growth factor, BMP2 bone morphogenic protein 2, BMP4 bone morphogenic protein 4, KGF keratinocyte growth factor, HGF hepatocyte growth factor, DMSO dimethyl sulfoxide, KOSR knockout serum replacement, FBS fetal bovine serum, HC hydrocortisone, CHIR99021-6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1*h*-imidazol-2-yl)-2-pyrimidinylamino]ethyl]amino]-3-pyridinecarboximidate, LY294002-2-(Morpholin-4-yl)-8-phenyl-4*H*-chromen-4-one, NQ expressed but not quantified, NT not tested

Pluripotent Stem Cell-Derived Human Tissue




Fig. 1. Stagewise differentiation of pluripotent stem cells to hepatocyte-like cells. Pluripotent stem cells are differentiated to definitive endoderm, then primed to the hepatoblast stage. Following this, the progenitors are matured to hepatocyte-like cells. A panel of markers can be employed to assess successful differentiation at each stage of the process. Those include; OCT3/4 - octamer-binding transcription factor 4, SSEA-4—stage-specific embryonic antigen 4, SSEA-3—stage-specific embryonic antigen 3, GATA2 - GATA binding protein 2, GATA4—GATA binding protein 4, GATA6—GATA binding protein 6, FOXA2—forkhead box protein A2, FOXA1—forkhead box protein A1, FGF17—fibroblast growth factor 17, hHex—hematopoietically-expressed homeobox, HNF4α—hepatocyte nuclear factor 4 alpha, HNF1α—hepatocyte nuclear factor 1 alpha, AFP—alpha-fetoprotein, CK8—cytokeratin 8, CK18—cytokeratin 18, CK19—cytokeratin 19, GSTA1—glutathione S-transferase A1, APOA1—apolipoprotein A1, MRP2—multidrug resistance-associated protein 2, CYP1A2—cytochrome P450 1A2, CYP2A6—cytochrome P450 2A6, CYP2B6—cytochrome P450 2B6, CYP2C9—cytochrome P450 2C9, CYP3A4—cytochrome P450 3A4, CYP3A7—cytochrome P450 3A7

suggesting that further maturation of the HLCs is likely required. Similarly, Tasnim *et al.* encapsulated human pluripotent stem cell-derived hepatocyte-like cells in galactosylated cellulosic sponges, which promoted the formation and retention of spheroids (69); such spheroids were more sensitive to the toxicity of hepatotoxic drugs as compared to conventional monolayers, and responses in stem cell spheroids were like those observed in PHHs. The above-mentioned approaches to form spheroids typically result in a randomly distributed/heterogeneous architecture. In contrast, Ma *et al.* utilized bioprinting to create liver lobule-like hexagonal organoids containing HLCs, endothelial cells, and adipose-derived stem cells embedded in a hydrogel (70). Liver gene expression and functions in co-cultured organoids were detected for ~ 32 days at higher levels than in mono-cultures. Ultimately, standardization of protocols to form spheroids via different approaches, as well as cost reduction, will be required for routine deployment in drug development.

The engineering approaches described above improve HLC function, but do not always elucidate the microenvironmental signals (and their combinations) underlying the observed responses. On the other hand, cellular microarrays, in which viable cells are seeded onto printed spots of materials/biomolecules, represent a powerful approach for precisely defining the optimal microenvironment of cells (71–75). Cellular microarrays based on spotted biomaterial libraries have been applied to several investigations aimed at exploring stem cell functions on changing polymer backbone chemistries and end-group functionalization (76–80). For instance, Kaylan *et al.* utilized an ECM microarray approach to demonstrate that ECM composition exhibits a significant influence on the adhesion and degree of differentiation of mouse liver progenitor cells when they are

induced to differentiate (81). We anticipate that the use of cellular microarrays for defining precise molecular conditions for HLC differentiation will continue to grow in this field.

STEM CELL-DERIVED CARDIOMYOCYTES

Differentiation of Cardiomyocytes from Pluripotent Stem Cells

In 2006 and 2007, Takahashi and Yamanaka demonstrated that the introduction of specific factors into differentiated fibroblasts, of fetal and adult origin, induce cellular reprogramming into PSCs (82,83). The generation of iPSCs from differentiated fibroblasts is achieved through viral expression of the transcription factors such as Oct4, Sox2, Klf4, and cMyc. Further differentiation of iPSC into cardiomyocytes can be performed using several methods, including the traditional embryoid body formation, activation/inhibition of signaling pathways with specific proteins, and modulation of the Wnt signaling pathway via small molecule regulators. Most of the current protocols for the generation of cardiomyocytes from iPSC result in mixtures of ventricular, atrial and nodal-like cardiomyocytes (84).

Cardiomyocytes derived from iPSCs maintain an immature phenotype in culture. For example, iPSC-derived cardiomyocytes are small, have irregular shapes, and exhibit lower membrane capacitance in comparison to mature cardiomyocytes. Structurally, iPSC-derived cardiomyocytes are mono- rather than bi- or multi-nucleated cells that lack T-tubules, have disarrayed sarcomeres with immature patterns of myofibrillar isoforms, and have relatively low mitochondrial content. iPSC cardiomyocytes use glucose instead of fatty acids as a

metabolic substrate. iPSC-derived cardiomyocytes and mature cardiomyocytes also exhibit differences in relevant electrophysiological parameters (e.g., upstroke velocity, and resting membrane potential), contractile force, Ca²⁺ handling properties, and response to beta adrenergic stimulation (84). Several approaches are being tested to induce phenotypic maturation of iPSC-cardiomyocytes. These strategies are based on long-term culture, the use of topographical and biochemical cues, and co-culture with other cell types (85). Exploitation of the full potential of the iPSC-cardiomyocyte model for research and clinical applications still requires the development of strategies for the induction of mature cellular phenotypes. These strategies need to be reproducible, amenable to large scale culturing and screening applications, and suitable to produce “clinical grade” cells.

iPSC-Derived Cardiomyocytes in Pharmaceutical Development

iPSC-derived cardiomyocytes are an attractive model for pharmaceutical research applications. The use of iPSC-derived cardiomyocytes in the context of pharmaceutical applications can be divided in two broad categories: (1) screening of drug candidates to identify compounds with cardiotoxic potential, and (2) *in vitro* modeling of cardiac diseases for the identification and validation of pharmacological targets. In general, cultures of iPSC cardiomyocytes are suitable for medium to high-throughput assays and high content imaging. There are diverse functional screening platforms that provide a range of information derived from the analysis of either single cells or multiple cells per well (for a review please see (86)). Cellular parameters such as contractility, membrane depolarization, and motion are inferred from the analysis of various readouts derived from fluorescent and luminescent Ca²⁺ indicators, small molecule voltage probes, patch clamp, multi-electrode arrays, impedance measurements, and bright field microscopy.

Examples of the Use of iPSC-Derived Cardiomyocytes for Drug Toxicity Studies

The iPSC-derived cardiomyocyte model has become a popular platform for evaluating the impact of drugs on various cellular parameters relevant to cardiac physiology. Some examples include early work by Tanaka *et al.* investigating the effects of ion channel inhibitors and beta-adrenergic agonists on electrophysiological properties (e.g., field potential waveform) of human iPSC-cardiomyocytes (87). Work by Yokoo *et al.* demonstrated that drugs that affect cardiac beating frequency and contractility in the clinic (e.g., adrenaline, isoproterenol, procainamide, and verapamil) also modify beating parameters on iPSC-cardiomyocytes (88). Also, early work by Braam *et al.* described the development of “chip-based” approaches amenable to medium to high-throughput modalities to facilitate the evaluation of drugs by measuring changes in action potential in clusters of electrically connected iPSC-cardiomyocytes. The authors evaluated a range of cardioactive and non-cardioactive compounds; in general, the iPSC-cardiomyocyte model was a good predictor of clinical effects (89). In a landmark study, Moretti *et al.* derived patient-specific iPSC-cardiomyocytes from two patients (and two non-affected controls) with long QT-syndrome; patient-derived iPSC-cardiomyocytes exhibited electrophysiological alterations typical of the syndrome and had increased susceptibility to catecholamine-induced tachyarrhythmia (90). The generation

and evaluation of “libraries” of iPSC-cardiomyocytes from patients with different genetic cardiac disorders allows evaluating whether differences in susceptibility to cardiotoxic drugs are associated to the individual’s genetic background (91). This paradigm has been extended towards the characterization of molecular determinants for drug-induced cardiotoxicity in other clinical settings. For example, an interesting study by Burridge *et al.* showed that iPSC-cardiomyocytes derived from patients with breast cancer who developed anthracycline-related cardiotoxicity were more susceptible to doxorubicin toxicity than iPSC-cardiomyocytes from similarly treated patients who did not develop cardiotoxicity (92). Recent advancements in genome editing technologies will allow the generation of engineered iPSC-cardiomyocyte lines to examine the role of genetic variants during the development of specific types of drug cardiotoxicity.

MOVING BEYOND CURRENT *IN VITRO* LIMITATIONS

Despite the advances, further refinement is required to better model the physiology of the organ of interest. Doing so will increase specificity and sensitivity of the screening models, thereby reducing the potential for off target drug events and failure. The ability to move beyond the current limitations requires interdisciplinary collaboration. By combining the best stem cell models with chemistry, physics, and engineering, new automated screening assays with improved function and physiology can be developed. Current areas of promise are discussed in the final section.

Biomaterials and Scaffolds for *In Vitro* Model Maturation

Biomaterials and recombinant extra-cellular matrices have been shown to improve cell phenotype and cell maturity (93,94) in both hepatocytes (8) and cardiomyocytes (95) when cultured within 2D or 3D platforms. Organoid encapsulation by hydrogels such as alginate can be used for controlling the maturation, size and microenvironment of developing organoids (94,96). Moreover, hydrogels can be supplemented with specific ECM proteins or growth factors to mimic a specific tissue or disease environment for improved modeling. Current biomaterials have proven cost-effective and highly reproducible towards significantly reducing batch variation. Scaffolds can be obtained from natural materials such as laminins, alginate, or hyaluronic acid (8,95,97) or synthetic materials such as polyvinyl alcohol (PVA), polylactide-co-glycolide (PLG), poly [2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl) ammonium hydroxide] (PMEDSAH) or poly (caprolactone) (PCL), (93,98).

Automation and High Content Analysis as an Efficient Scale Up Production of ES-Derived Models

For screening purposes, stem cell differentiation procedures must be fully reproducible, display low levels of variation between wells and plates and be amenable to high content analysis and multiplexing. Automation of the protocols and a high-throughput assay development is pivotal for this; automated liquid handling systems allows the generation of large quantities of cells with reduced variation making them suitable for testing large compound libraries. Combining this with multiparametric profiling assays such as automated microscopy (99,100) or high-throughput genomics (101) allows the user to

Pluripotent Stem Cell-Derived Human Tissue

create a multi-parametric profile in response to the test compounds. Recent studies have probed the practical use of stem cell technology for high content screening for toxic drugs by a combination of high content microscopy and single endpoint assays (6,102). A clear example of the significance of these technologies is captured by the work of Bray at (103,104). They tested over 30,000 small molecules in a cell line using the “cell paint” assay, a multiplexed assay that allows in-depth morphological and organelle profiling at an acceptable cost. *in vitro* organ-on-chip for as a multiorgan toxicity model.

While hepatotoxicity and cardiotoxicity are critical issues to address during pharmaceutical drug development, drugs can also cause toxicity to other organ systems resulting in adverse outcomes. Thus, culture platforms that can adequately mimic organ-organ interaction upon drug exposure are also required. By combining microfluidics, micropatterning, and 3D cultures, it is now possible to model organ microenvironment and organ-organ interaction (105,106). Such “human-on-a-chip” systems modulate the physiological fluid shear stress and can maintain a constant delivery of oxygen to the system, while also enabling paracrine communication between multiple tissue types via the flowing culture medium. Recently, Maschmeyer *et al.* (107) created an organ-on-a-chip platform that allowed paracrine interaction of 4 tissue types, namely intestine, liver, skin and kidney. This platform was used to study ADME and repeated dose toxicity testing, providing proof of concept of such an approach. We anticipate that adaptation of organ-on-a-chip technology to stem-cell-derived differentiated cells will offer a powerful tool to study mechanism of drug target and off target effects before progressing to *in vivo* testing.

CONCLUSION

We believe that with the recent advances in stem cell differentiation, scale up, and performance, it is possible to create more accurate human tissue models for drug development. Advances in stem cell biology over the last decade has provided the field with more accurate human cell-based models that recapitulate key aspects of human drug metabolism, with better precision than cancer lines. These systems also provide comparable activity to primary cells. While this is encouraging, further improvements are necessary to improve predictive power. Tissue engineering has already played an important role in this space, with organ-on-chip devices now available via several commercial sources. Future efforts in the field should focus on developing high-throughput multi-organ systems, capable of real-time monitoring and multiplexing to reduce costs and improve the quality of data output.

Funding Information Mr. Jose Meseguer Ripollés was funded by a MRC PhD studentship. Prof David Hay was supported by funding from the UK Regenerative Medicine Platform (MR/K026666/1 and MR/L022974/1). Dr. Javier Blanco was supported by the National Institute of General Medical Science, award GM073646. Dr. Salman Khetani was supported by the National Institute of Environmental Health Sciences, award ES027622, and US National Science Foundation, award CBET-1351909.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in

any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

1. Harrison RK. Phase II and phase III failures: 2013–2015. *Nat Rev Drug Discov.* 2016;15(12):817–8.
2. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. *BMC Med.* 2016;14:10.
3. Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D, et al. Screening out irrelevant cell-based models of disease. *Nat Rev Drug Discov.* 2016;15(11):751–69.
4. Burkhardt B, Martinez-Sanchez JJ, Bachmann A, Ladurner R, Nüssler AK. Long-term culture of primary hepatocytes: new matrices and microfluidic devices. *Hepatol Int.* 2014;8(1):14–22.
5. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, Storck C, Zhou W, Iredale JP, et al. Accurate prediction of drug-induced liver injury using stem cell-derived populations. *Stem Cells Transl Med.* 2014;3(2):141–8.
6. Grimm FA, Iwata Y, Sirenko O, Bittner M, Rusyn I. High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes. *Assay Drug Dev Technol.* 2015;13(9):529–46.
7. Gao X, Liu Y. A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better *in vitro* model of hepatotoxicity than most hepatoma cell lines. *Cell Biol Toxicol.* 2017;31:1–15.
8. Cameron K, Tan R, Schmidt-Heck W, Campos G, Lyall MJ, Wang Y, et al. Recombinant laminins drive the differentiation and self-organization of hESC-derived hepatocytes. *Stem Cell Rep.* 2015;5(6):1250–62.
9. Davidson MD, Ware BR, Khetani SR. Stem cell-derived liver cells for drug testing and disease modeling. *Discov Med.* 2015;19(106):349–58.
10. Rajamohan D, Kalra S, Duc Hoang M, George V, Staniforth A, Russell H, et al. Automated electrophysiological and pharmacological evaluation of human pluripotent stem cell-derived cardiomyocytes. *Stem Cells Dev.* 2016;25(6):439–52.
11. O'Brien PJ. High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and *in vivo* use as translational safety biomarkers. *Basic Clin Pharmacol Toxicol.* 2014;115(1):4–17.
12. Cameron K, Marriage H, Hay D, Medine C. Stem cell-derived cardiomyocytes and hepatocytes as tools for drug development and screening applications. In: Vertès AA, Qureshi N, Caplan AI, Babiss LE, editors. *Stem Cells in Regenerative Medicine* [Internet]. John Wiley & Sons, Ltd; 2015 [cited 2017 Jan 20]. p. 171–92. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/9781118846193.ch9/summary>.
13. Lynch T, Price AL. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. *Am Fam Physician.* 2007;76(3):391–6.
14. Daly AK. Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury? *Pharm Res.* 2017;34(8):1564–9.
15. Copple IM, Goldring CE, Kitteringham NR, Park BK. The Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity. In: *Adverse Drug Reactions* [Internet]. Springer, Berlin, Heidelberg; 2010 [cited 2017 Nov 5]. p. 233–66. (Handbook of Experimental Pharmacology). Available from: https://link.springer.com/chapter/10.1007/978-3-642-00663-0_9.
16. Köhler UA, Böhm F, Rolf F, Egger M, Hornemann T, Pasparakis M, et al. NF- κ B/RelA and Nrf2 cooperate to

- maintain hepatocyte integrity and to prevent development of hepatocellular adenoma. *J Hepatol.* 2016;64(1):94–102.
17. Decker CW, Casian JG, Nguyen KT, Horton LA, Rao MP, Silkwood KH, *et al.* The critical role of mitochondria in drug-induced liver injury. In: *Molecules, Systems and Signaling in Liver Injury* [Internet]. Springer, Cham; 2017 [cited 2017 Nov 5]. p. 159–81. (Cell Death in Biology and Diseases). Available from: https://link.springer.com/chapter/10.1007/978-3-319-58106-4_8.
 18. Han D, Dara L, Win S, Than TA, Yuan L, Abbasi SQ, *et al.* Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. *Trends Pharmacol Sci.* 2013;34(4):243–53.
 19. Sano R, Reed JC. ER stress-induced cell death mechanisms. *Biochim Biophys Acta.* 2013;1833(12):3460–70.
 20. Foufelle F, Fromenty B. Role of endoplasmic reticulum stress in drug-induced toxicity. *Pharmacol Res Perspect* [Internet]. 2016 Feb 4 [cited 2017 Nov 7];4(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777263/>.
 21. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, *et al.* Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation.* 2017;135(10):e146–603.
 22. Mordwinkin NM, Burrige PW, Wu JC. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. *J Cardiovasc Transl Res.* 2013;6(1):22–30.
 23. Soldatow VY, LeCluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. *Toxicol Res.* 2013;2(1):23–39.
 24. Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT. Competency of different cell models to predict human hepatotoxic drugs. *Expert Opin Drug Metab Toxicol.* 2014;10(11):1553–68.
 25. van de Meer BJ, Tertoolen LG, Mummery CL. Concise review: measuring physiological responses of human pluripotent stem cell derived cardiomyocytes to drugs and disease. *Stem Cells.* 2016 Aug;34(8):2008–15.
 26. Szkolnicka D, Hay DC. Concise review: Advances in generating hepatocytes from pluripotent stem cells for translational medicine. *Stem Cells.* 2016 Jun;34(6):1421–6.
 27. Donato MT, Jover R, Gómez-Lechón MJ. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. *Curr Drug Metab.* 2013;14(9):946–68.
 28. Castell JV, Jover R, Martínez-Jiménez CP, Gómez-Lechón MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. *Expert Opin Drug Metab Toxicol.* 2006;2(2):183–212.
 29. Takayama K, Mizuguchi H. Generation of human pluripotent stem cell-derived hepatocyte-like cells for drug toxicity screening. *Drug Metab Pharmacokinet* [Internet]. [cited 2017 Jan 19]; Available from: <http://www.sciencedirect.com/science/article/pii/S1347436716300799>.
 30. Pradip A, Steel D, Jacobsson S, Holmgren G, Ingelman-Sundberg M, Sartipy P, *et al.* High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis. *Stem Cells Int.* 2016;2016:e2475631.
 31. Takayama K, Morisaki Y, Kuno S, Nagamoto Y, Harada K, Furukawa N, *et al.* Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPSC-derived hepatocytes. *Proc Natl Acad Sci U S A.* 2014;111(47):16772–7.
 32. Ware BR, Berger DR, Khetani SR. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. *Toxicol Sci.* 2015;145(2):252–62.
 33. Szkolnicka D, Lucendo-Villarin B, Moore JK, Simpson KJ, Forbes SJ, Hay DC. Reducing hepatocyte injury and necrosis in response to paracetamol using noncoding RNAs. *Stem Cells Transl Med.* 2016;5(6):764–72.
 34. Choudhury Y, Toh YC, Xing J, Qu Y, Poh J, Huan L, *et al.* Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. *Sci Rep.* 2017;7:41238.
 35. Choi SM, Kim Y, Shim JS, Park JT, Wang R-H, Leach SD, *et al.* Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. *Hepatology.* 2013;57(6):2458–68.
 36. Guan Y, Xu D, Garfin PM, Ehmer U, Hurwitz M, Enns G, *et al.* Human hepatic organoids for the analysis of human genetic diseases. *JCI Insight.* 2017;7:2(17).
 37. Hindley CJ, Cordero-Espinoza L, Huch M. Organoids from adult liver and pancreas: stem cell biology and biomedical utility. *Dev Biol.* 2016;420(2):251–61.
 38. Iii RLG, Hannan NRF, Bort R, Hanley NA, Drake RAL, Cameron GWW, *et al.* Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. *PLoS One.* 2014;9(1):e86372.
 39. Cai J, Zhao Y, Liu Y, Ye F, Song Z, Qin H, *et al.* Directed differentiation of human embryonic stem cells into functional hepatic cells. *Hepatology.* 2007;45(5):1229–39.
 40. Agarwal S, Holton KL, Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. *Stem Cells Dayt Ohio.* 2008;26(5):1117–27.
 41. Hay DC, Fletcher J, Payne C, Terrace JD, Gallagher RCJ, Snoeys J, *et al.* Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. *Proc Natl Acad Sci U S A.* 2008;105(34):12301–6.
 42. Basma H, Soto-Gutiérrez A, Yannam GR, Liu L, Ito R, Yamamoto T, *et al.* Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. *Gastroenterology.* 2009;136(3):990–9.
 43. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, *et al.* Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. *Hepatology.* 2010;51(1):297–305.
 44. Sullivan GJ, Hay DC, Park I-H, Fletcher J, Hannoun Z, Payne CM, *et al.* Generation of functional human hepatic endoderm from human induced pluripotent stem cells. *Hepatology.* 2010;51(1):329–35.
 45. Touboul T, Hannan NRF, Corbinau S, Martinez A, Martinet C, Branchereau S, *et al.* Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. *Hepatology.* 2010;51(5):1754–65.
 46. Rashid ST, Corbinau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, *et al.* Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. *J Clin Invest.* 2010;120(9):3127–36.
 47. Chen Y-F, Tseng C-Y, Wang H-W, Kuo H-C, Yang VW, Lee OK. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. *Hepatology.* 2012;55(4):1193–203.
 48. Rashidi H, Alhaque S, Szkolnicka D, Flint O, Hay DC. Fluid shear stress modulation of hepatocyte-like cell function. *Arch Toxicol.* 2016;90:1757–61.
 49. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, *et al.* Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. *Cell Res.* 2009;19(11):1233–42.
 50. Wang Y, Alhaque S, Cameron K, Meseguer-Ripolles J, Lucendo-Villarin B, Rashidi H, *et al.* Defined and scalable generation of hepatocyte-like cells from human pluripotent stem cells. *JoVE J Vis Exp.* 2017;(121):e55355.
 51. D'Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efficient differentiation of human embryonic stem cells to definitive endoderm. *Nat Biotechnol.* 2005;23(12):1534–41.
 52. Ware BR, Khetani SR. Engineered liver platforms for different phases of drug development. *Trends Biotechnol.* 2017;35(2):172–83.
 53. Baxter M, Withey S, Harrison S, Segeritz C-P, Zhang F, Atkinson-Dell R, *et al.* Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. *J Hepatol.* 2015;62(3):581–9.
 54. Cayo MA, Mallanna SK, Di Furio F, Jing R, Tolliver LB, Bures M, *et al.* A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia. *Cell Stem Cell.* 2017;20(4):478–489.e5.
 55. Graffmann N, Ring S, Kawala M-A, Wruck W, Ncube A, Trompeter H-I, *et al.* Modeling nonalcoholic fatty liver disease with human pluripotent stem cell-derived immature

Pluripotent Stem Cell-Derived Human Tissue

- hepatocyte-like cells reveals activation of PLIN2 and confirms regulatory functions of peroxisome proliferator-activated receptor alpha. *Stem Cells Dev.* 2016;25(15):1119–33.
56. Kim DE, Jang M-J, Kim YR, Lee J-Y, Cho EB, Kim E, et al. Prediction of drug-induced immune-mediated hepatotoxicity using hepatocyte-like cells derived from human embryonic stem cells. *Toxicology.* 2017;387(Supplement C):1–9.
 57. Lucendo-Villarin B, Filis P, Swortwood MJ, Huestis MA, Meseguer-Ripolles J, Cameron K, et al. Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells. *Arch Toxicol.* 2017.
 58. Kang S-J, Lee H-M, Park Y-I, Yi H, Lee H, So B, et al. Chemically induced hepatotoxicity in human stem cell-induced hepatocytes compared with primary hepatocytes and HepG2. *Cell Biol Toxicol.* 2016;32(5):403–17.
 59. Szkolnicka D, Zhou W, Lucendo-Villarin B, Hay DC. Pluripotent stem cell-derived hepatocytes: Potential and challenges in pharmacology. *Annu Rev Pharmacol Toxicol.* 2013;53:147–59.
 60. Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. *Hepatology* Baltim Md. 2015;61(4):1370–81.
 61. Khetani SR, Szulgit G, Del Rio JA, Barlow C, Bhatia SN. Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. *Hepatology* Baltim Md. 2004;40(3):545–54.
 62. Khetani SR, Chen AA, Ranscht B, Bhatia SN. T-cadherin modulates hepatocyte functions in vitro. *FASEB J.* 2008;22(11):3768–75.
 63. Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. *Toxicol Sci Off J Soc Toxicol.* 2013;132(1):107–17.
 64. Bell CC, Hendriks DFG, Moro SML, Ellis E, Walsh J, Renblom A, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. *Sci Rep.* 2016;6:25187.
 65. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. *Biomaterials.* 2013;34(7):1781–9.
 66. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature.* 2013;499(7459):481–4.
 67. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MMA, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. *Cell.* 2015;160(1–2):299–312.
 68. Acikgöz A, Giri S, Cho M-G, Bader A. Morphological and functional analysis of hepatocyte spheroids generated on poly-HEMA-treated surfaces under the influence of fetal calf serum and nonparenchymal cells. *Biomol Ther.* 2013;3(1):242–69.
 69. Tasnim F, Toh Y-C, Qu Y, Li H, Phan D, Narmada BC, et al. Functionally enhanced human stem cell derived hepatocytes in galactosylated cellulose sponges for hepatotoxicity testing. *Mol Pharm.* 2016;13(6):1947–57.
 70. Ma X, Qu X, Zhu W, Li Y-S, Yuan S, Zhang H, et al. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. *Proc Natl Acad Sci.* 2016 Feb 23;113(8):2206–11.
 71. Flaim CJ, Chien S, Bhatia SN. An extracellular matrix microarray for probing cellular differentiation. *Nat Methods.* 2005;2(2):119–25.
 72. Brafman DA, de Minicis S, Seki E, Shah KD, Teng D, Brenner D, et al. Investigating the role of the extracellular environment in modulating hepatic stellate cell biology with arrayed combinatorial microenvironments. *Integr Biol Quant Biosci Nano Macro.* 2009;1(8–9):513–24.
 73. Brafman DA, Shah KD, Fellner T, Chien S, Willert K. Defining long-term maintenance conditions of human embryonic stem cells with arrayed cellular microenvironment technology. *Stem Cells Dev.* 2009;18(8):1141–54.
 74. Soen Y, Mori A, Palmer TD, Brown PO. Exploring the regulation of human neural precursor cell differentiation using arrays of signaling microenvironments. *Mol Syst Biol.* 2006;2:37.
 75. LaBarge MA, Nelson CM, Villadsen R, Fridriksdottir A, Ruth JR, Stampfer MR, et al. Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. *Integr Biol Quant Biosci Nano Macro.* 2009;1(1):70–9.
 76. Anderson DG, Levenberg S, Langer R. Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. *Nat Biotechnol.* 2004;22(7):863–6.
 77. Unadkat HV, Hulsman M, Cornelissen K, Papenburg BJ, Truckenmüller RK, Carpenter AE, et al. An algorithm-based topographical biomaterials library to instruct cell fate. *Proc Natl Acad Sci U S A.* 2011;108(40):16565–70.
 78. Mei Y, Saha K, Bogatyrev SR, Yang J, Hook AL, Kalcioğlu ZI, et al. Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. *Nat Mater.* 2010;9(9):768–78.
 79. Saha K, Mei Y, Reisterer CM, Pyzocha NK, Yang J, Muffat J, et al. Surface-engineered substrates for improved human pluripotent stem cell culture under fully defined conditions. *Proc Natl Acad Sci U S A.* 2011;108(46):18714–9.
 80. Zhang R, Liberski A, Sanchez-Martin R, Bradley M. Microarrays of over 2000 hydrogels—identification of substrates for cellular trapping and thermally triggered release. *Biomaterials.* 2009;30(31):6193–201.
 81. Kaylan KB, Ermilova V, Yada RC, Underhill GH. Combinatorial microenvironmental regulation of liver progenitor differentiation by Notch ligands, TGFβ, and extracellular matrix. *Sci Rep* [Internet]. 2016 Mar 30 [cited 2017 Sep 19];6. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812246/>.
 82. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell.* 2007;131(5):861–72.
 83. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell.* 2006;126(4):663–76.
 84. Kolanowski TJ, Antos CL, Guan K. Making human cardiomyocytes up to date: derivation, maturation state and perspectives. *Int J Cardiol* [Internet]. [cited 2017 May 31]; Available from: <http://www.sciencedirect.com/science/article/pii/S0167527317300517>.
 85. Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. *Circ Res.* 2014;114(3):511–23.
 86. Del Álamo JC, Lemons D, Serrano R, Savchenko A, Cerignoli F, Bodmer R, et al. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. *Biochim Biophys Acta.* 2016;1863(7 Pt B):1717–27.
 87. Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H, et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. *Biochem Biophys Res Commun.* 2009;385(4):497–502.
 88. Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. *Biochem Biophys Res Commun.* 2009;387(3):482–8.
 89. Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. *Stem Cell Res.* 2010;4(2):107–16.
 90. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med.* 2010;363(15):1397–409.
 91. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. *Circulation.* 2013;127(16):1677–91.
 92. Burridge PW, Li YF, Matsa E, Wu H, Ong S-G, Sharma A, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. *Nat Med.* 2016;22(5):547–56.
 93. Lucendo-Villarin B, Rashidi H, Cameron K, Hay DC. Pluripotent stem cell derived hepatocytes: using materials to

- define cellular differentiation and tissue engineering. *J Mater Chem B*. 2016;4(20):3433–42.
94. Jitraruch S, Dhawan A, Hughes RD, Filippi C, Soong D, Philippeos C, et al. Alginate microencapsulated hepatocytes optimised for transplantation in acute liver failure. *PLoS One*. 2014;9(12):e113609.
 95. Patel AK, Celiz AD, Rajamohan D, Anderson DG, Langer R, Davies MC, et al. A defined synthetic substrate for serum-free culture of human stem cell derived cardiomyocytes with improved functional maturity identified using combinatorial materials microarrays. *Biomaterials*. 2015;61:257–65.
 96. Maguire T, Davidovich AE, Wallenstein EJ, Novik E, Sharma N, Pedersen H, et al. Control of hepatic differentiation via cellular aggregation in an alginate microenvironment. *Biotechnol Bioeng*. 2007;98(3):631–44.
 97. Ja KPMM, Miao Q, Zhen Tee NG, Lim SY, Nandihalli M, J A Ramachandra C, et al. iPSC-derived human cardiac progenitor cells improve ventricular remodelling via angiogenesis and interstitial networking of infarcted myocardium. *J Cell Mol Med*. 2016;20(2):323–32.
 98. Qian X, Villa-Diaz LG, Kumar R, Lahann J, Krebsbach PH. Enhancement of the propagation of human embryonic stem cells by modifications in the gel architecture of PMEDSAH polymer coatings. *Biomaterials*. 2014;35(36):9581–90.
 99. Chen WLK, Likhitpanichkul M, Ho A, Simmons CA. Integration of statistical modeling and high-content microscopy to systematically investigate cell–substrate interactions. *Biomaterials*. 2010 Mar;31(9):2489–97.
 100. The potential of high-content high-throughput microscopy in drug discovery - Starkuviene - 2007 - *British Journal of Pharmacology* - Wiley Online Library [Internet]. [cited 2017 Mar 30]. Available from: <http://onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0707346/full>.
 101. Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. *Nat Rev Genet*. 2015;16(5):299–311.
 102. Sirenko O, Hesley J, Rusyn I, Cromwell EF. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. *ASSAY Drug Dev Technol*. 2013;12(1):43–54.
 103. Bray M-A, Gustafsdottir SM, Ljosa V, Singh S, Sokolnicki KL, Bittker JA, et al. A dataset of images and morphological profiles of 30,000 small-molecule treatments using the Cell Painting assay. *GigaScience* [Internet]. [cited 2017 May 25]; Available from: <https://academic.oup.com/gigascience/article/doi/10.1093/gigascience/giw014/2865213/A-dataset-of-images-and-morphological-profiles-of>.
 104. Bray M-A, Singh S, Han H, Davis CT, Borgeson B, Hartland C, et al. Cell painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. *Nat Protoc*. 2016 Sep;11(9):1757–74.
 105. Verhulsel M, Vignes M, Descroix S, Malaquin L, Vignjevic DM, Viovy J-L. A review of microfabrication and hydrogel engineering for micro-organs on chips. *Biomaterials*. 2014 Feb;35(6):1816–32.
 106. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. *Trends Cell Biol*. 2011 Dec;21(12):745–54.
 107. Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hübner J, et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. *Lab Chip*. 2015 Jun 21;15(12):2688–99.